The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin

• Published in: Radiology and oncology 2016-03, Vol.50 (1), p.113-120
• Main Authors: Oblak, Irena, Cesnjevar, Monika, Anzic, Mitja, Hadzic, Jasna But, Ermenc, Ajra Secerov, Anderluh, Franc, Velenik, Vaneja, Jeromen, Ana, Korosec, Peter
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; anaemia; anal canal squamous cell carcinoma; Anemia; Brachytherapy; Canals (anatomy); Cancer; Chemoradiotherapy; Chemotherapy; Clinical outcomes; Colorectal cancer; Confidence intervals; Disease control; Hemoglobin; Medical prognosis; Mitomycin C; Multivariate analysis; Radiation; Radiation therapy; radiochemotherapy; Squamous cell carcinoma; Statistical analysis; Survival
• ISSN: 1318-2099; 1581-3207; 1581-3207; 0485-893X
• DOI: 10.1515/raon-2015-0015

Radiochemotherapy is the main treatment for patients with squamous cell carcinoma of the anal canal. Anaemia is reported to have adverse effect on survival in cancer patients. The aim of the study was to evaluate the influence of anaemia on radiochemotherapy treatment outcome in patients with squamous cell carcinoma of the anal canal. One hundred consecutive patients with histologically confirmed squamous cell carcinoma of the anal canal were treated radically with 3-dimensional conformal or intensity-modulated radiation therapy followed by brachytherapy or external beam radiotherapy boost and with concurrent mitomycin C and 5-fluorouracil. The influence on survival of pre-treatment, mean on-treatment and end-of-treatment haemoglobin (Hb) concentrations was studied. The 5-year locoregional control, disease free survival, disease specific survival and overall survival rates for all patients were 72%, 71%, 77% and 62%, respectively. In univariate analysis, patients with pre-treatment and end-of-treatment Hb > 120 g/L survived statistically significantly better compared to patients with Hb ≤ 120 g/L. Patients with mean on-treatment Hb > 120 g/L only had statistically significant better locoregional control and overall survival than patients with Hb ≤ 120 g/L. In multivariate analysis, independent prognostic factors were pre-treatment Hb (> 120 g/L vs. ≤ 120 g/L) for overall survival (hazard ratio [HR] = 0.419, 95% confidence interval [CI] = 0.190-0.927, p = 0.032) and stage (I & II vs. III) for disease specific (HR = 3.523, 95% CI = 1.375-9.026, p = 0.009) and overall survival (HR = 2.230, 95% CI = 1.167-4.264, p = 0.015). The pre-treatment, mean on-treatment and end-of-treatment Hb concentration > 120 g/L carried better prognosis for patients for with squamous cell carcinoma of the anal canal treated with radiochemotherapy. The pre-treatment Hb > 120 g/L was an independent prognostic factor for overall survival of patients with anal canal cancer.